SOLIGENIX INC

SNGX represents the common stock of Soligenix, Inc., a late-stage biopharmaceutical company. The ticker trades on the Nasdaq Capital Market, allowing investors to buy and sell shares during regular U.S. market hours. SNGX stock gives shareholders an ownership interest in the company and its drug development programs. Because it is a small-cap biopharma stock, its price can be sensitive to clinical trial updates, regulatory news, and financing activities. For current details about SNGX, refer to the stock data displayed on this page.

Recent performance for SNGX depends on the latest trading activity, which can change daily. The most accurate recent price change, percentage move, and volume are shown in the live quote and performance section on this page. SNGX is a small-cap biopharmaceutical stock, so its price can react sharply to company-specific news such as trial results, regulatory developments, or financing updates. Review the latest SNGX data on this page rather than relying on any single past snapshot.

Valuation for SNGX is typically assessed using both market-based and company-specific measures. Investors may look at market capitalization, cash position, enterprise value, and the progress of its pipeline. Because SNGX is a clinical-stage biopharmaceutical company, traditional metrics like the P/E ratio may not be meaningful if earnings are negative or limited. Analysts often focus on potential commercial opportunities, trial timelines, and financing needs. Check the latest SNGX valuation data on this page for current figures.

To buy SNGX stock, you generally need a brokerage account that offers access to U.S. exchange-listed securities. Once your account is funded, you can search for the ticker SNGX, choose an order type such as market or limit, and submit your trade during market hours. Some brokers also allow extended-hours trading, subject to liquidity and eligibility. The minimum investment depends on your broker and the current share price of SNGX. Review the trading information shown on this page before placing an order.

SNGX carries risks common to small-cap biopharmaceutical companies. These include clinical trial failure, regulatory delays, dependence on limited product candidates, and the need for additional capital to fund research and operations. Share dilution may occur if the company raises money through equity offerings. Market liquidity and price volatility can also be significant for SNGX. Economic conditions and sector sentiment may further affect the stock. Review the risk disclosures and latest financial information on this page for a fuller picture.

SNGX has not historically paid regular cash dividends, which is common for clinical-stage biopharmaceutical companies that reinvest capital into research and development. Any future dividend decision would depend on the company's financial condition, cash needs, and board approval. For the most current dividend status of SNGX, including any announcements or special distributions, check the dividend section on this page. Investors seeking income should consider whether SNGX fits their objectives.